<DOC>
	<DOCNO>NCT02433392</DOCNO>
	<brief_summary>The purpose trial determine safety feasibility inject irinotecan hydrochloride drug-eluting bead directly cavity remain tumor surgically remove patient type brain tumor ( glioblastoma multiforme - also know glioma ) return prior therapy .</brief_summary>
	<brief_title>Study Intraparenchymal Therapy Adjunct Therapy Patients With Recurrent , Resectable Glioblastoma Multiforme .</brief_title>
	<detailed_description>A challenge treatment glioma delivery treatment brain systemic administration due blood brain barrier . To improve drug delivery brain achieve high local concentration anti-neoplastic agent low system toxicity , local regional approach propose . CM-BC2 , irinotecan hydrochloride drug-eluting bead , investigational medicinal product intend direction injection tumor resection margin . The objective trial demonstration safety feasibility intraparenchymal injection irinotecan hydrochloride drug-eluting bead treatment recurrent Glioblastoma multiforme .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>1. histologically confirm diagnosis Glioblastoma Multiforme ( GBM ) ( World Health Organization grade IV ) 2. recurrent disease 3. patient consider good candidate resection estimate life expectancy least 12 week estimate Principal Investigator designee . The decision opt resection recurrence must independent study selection . 4 . Tumour characteristic : Single unilateral supratentorial lesion On clinician 's assessment , must operable normal consideration risk vs. benefit condition prognosis 5. patient receive conventional treatment time initial diagnosis , include surgery ( biopsy debulking ) , and/or radiotherapy , and/or chemotherapy 6. male female ; racial exclusion ; least 18 year age 7 . Pregnancy must exclude female patient beta HCG ( Human Chorionic Gonadotropin ) ; patient agree use adequate contraception study duration 8 . Karnofsky Performance Status least 60 9 . Patients must able understand consent study instruction well follow prescribe instruction 10. patient must sign write informed consent prior study participation 1. patient must enrol clinical trial 30 day participation trial 2. history allergic reaction attribute compound similar chemical makeup composition CMBC2 , alginate irinotecan ; contraindication irinotecan therapy 3. open communication ventricle CSF ( cerebrospinal fluid ) tumour resection cavity/site must avoid . In case opening ventricle surgery , surgeon must decide whether effective closure possible obstruct gap Gelfoam/other appropriate material 4 . Tumor surgery , stereotactic biopsy GBM , neurosurgery within 30 day prior study entry 5 . Multiple GBM lesion 6 . Irinotecan chemotherapy within 30 day prior study treatment 7. radiotherapy stereotactic ( gamma knife ) radiosurgery within 90 day prior study entry 8. locoregional ( intracranial ) therapy treatment GBM , include administration biodegradable polymer wafer contain Carmustine and/or brachytherapy , 6 month prior study entry 9 . Significant liver function impairment : aminotransferase ( AST ) alanine transaminase ( ALT ) great 2.5 x upper limit normal ( ULN ) , total bilirubin great 2 x ULN 10. significant renal impairment : creatinine great 2.0 mg/dL 11 . Coagulopathy Prothrombin time ( PT ) partial thromboplastin time ( APTT ) less 1.5 x control , and/or platelet count le 100 x 10⁹/L 12 . Hb le 8 g/dL and/or neutrophil count ( ANC Absolute Neutrophil Count ) less 1 x 10⁹/L 13 . Any condition , investigator 's opinion , make patient 's best interest participate study 14 . Preexisting cerebral oedema , surgeon 's opinion , pose unacceptable risk postoperative oedema . This decision may time surgery . 15 . Presence concurrent malignancy , except adequately control limited basal cell carcinoma skin carcinoma situ cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>drug-eluting bead</keyword>
	<keyword>irinotecan hydrochloride</keyword>
</DOC>